Healthcare Sales & Marketing Network News: renal cell cancer

Searching News Database: renal cell cancer

HSMN NewsFeed - 12 Mar 2020
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 24 Oct 2019
European Symposium to Advance Adoption of MRI-Guided Radiation Therapy
Devices Radiology Oncology

HSMN NewsFeed - 10 May 2018
Lilly Announces Agreement To Acquire ARMO BioSciences
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 30 May 2017
Churchill Pharmaceuticals Expands Commercial Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Apr 2016
Hematogenix Laboratory Services, LLC (Hematogenix)- Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immuno-Oncology Therapies
Diagnostics Oncology Product Launch

HSMN NewsFeed - 25 Mar 2014
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jul 2011
St. Gallen International Breast Cancer Expert Panel Guidelines Include Oncotype DX(R) as Predictor of Chemotherapy Benefit
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 2 May 2011
Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX(R)
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 13 Sep 2010
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Oct 2009
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2009
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jun 2008
ArQule Announces Appointment of Brian Schwartz as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 May 2008
Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Premenopausal Women With Early-Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Dec 2007
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Sep 2007
CuraGen Appoints Clinical Oncologist as VP of Medical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2007
Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 1 Jun 2006
ZIOPHARM Appoints Brian Schwartz, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel

Return to NewsFeed

Additional items found! 33

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 33 additional stories matching:
renal cell cancer
(Password required)

FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!